CD9 and melanoma: The analysis performed on the plasma of healthy donors compared to melanoma patients clearly showed that the amount of all circulating exosomes in melanoma patients was higher than in healthy donors (tsg-101+/CD9+ exosomes), while the fraction of tsg-101+/CD56+ exosomes (NKExo) was significantly lower (Figure 10E).